Bibliography for INIM0031: Neoplasia and its Treatment BETA

Ajila, V. et al. (2015) ‘Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck’, Journal of Sexually Transmitted Diseases, 2015, pp. 1–5. Available at: https://doi.org/10.1155/2015/791024.

Barrett, D.M., Grupp, S.A. and June, C.H. (2015) ‘Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street’, The Journal of Immunology, 195(3), pp. 755–761. Available at: https://doi.org/10.4049/jimmunol.1500751.

Ecker, D.M., Jones, S.D. and Levine, H.L. (2015) ‘The therapeutic monoclonal antibody market’, mAbs, 7(1), pp. 9–14. Available at: https://doi.org/10.4161/19420862.2015.989042.

Gill, S. and June, C.H. (2015) ‘Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies’, Immunological Reviews, 263(1), pp. 68–89. Available at: https://doi.org/10.1111/imr.12243.

Grupp, S.A. et al. (2013) ‘Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia’, New England Journal of Medicine, 368(16), pp. 1509–1518. Available at: https://doi.org/10.1056/NEJMoa1215134.

Hanahan, D. and Weinberg, R.A. (2000) ‘The Hallmarks of Cancer’, Cell, 100(1), pp. 57–70. Available at: https://doi.org/10.1016/S0092-8674(00)81683-9.

zur Hausen, H. (2009) ‘Papillomaviruses in the causation of human cancers — a brief historical account’, Virology, 384(2), pp. 260–265. Available at: https://doi.org/10.1016/j.virol.2008.11.046.

Hodi, F.S. et al. (2010) ‘Improved Survival with Ipilimumab in Patients with Metastatic Melanoma’, New England Journal of Medicine, 363(8), pp. 711–723. Available at: https://doi.org/10.1056/NEJMoa1003466.

Jeggo, P.A., Pearl, L.H. and Carr, A.M. (2015) ‘DNA repair, genome stability and cancer: a historical perspective’, Nature Reviews Cancer, 16(1), pp. 35–42. Available at: https://doi.org/10.1038/nrc.2015.4.

Kaufman, H.L., Kohlhapp, F.J. and Zloza, A. (2015) ‘Oncolytic viruses: a new class of immunotherapy drugs’, Nature Reviews Drug Discovery, 14(9), pp. 642–662. Available at: https://doi.org/10.1038/nrd4663.

Klebanoff, C.A., Rosenberg, S.A. and Restifo, N.P. (2016) ‘Prospects for gene-engineered T cell immunotherapy for solid cancers’, Nature Medicine, 22(1), pp. 26–36. Available at: https://doi.org/10.1038/nm.4015.

Koebel, C.M. et al. (2007) ‘Adaptive immunity maintains occult cancer in an equilibrium state’, Nature, 450(7171), pp. 903–907. Available at: https://doi.org/10.1038/nature06309.

Larson, C. et al. (2015) ‘Going viral: a review of replication-selective oncolytic adenoviruses’, Oncotarget, 6(24). Available at: https://doi.org/10.18632/oncotarget.5116.

Lazebnik, Y. (2010) ‘What are the hallmarks of cancer?’, Nature Reviews Cancer, 10(4), pp. 232–233. Available at: https://doi.org/10.1038/nrc2827.

Lingyun Geng (2015) ‘Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments’, International Journal of Clinical and Experimental Medicine, 8(9). Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658837/.

de Martel, C. et al. (2012) ‘Global burden of cancers attributable to infections in 2008: a review and synthetic analysis’, The Lancet Oncology, 13(6), pp. 607–615. Available at: https://doi.org/10.1016/S1470-2045(12)70137-7.

Matsuoka, M. and Jeang, K.-T. (2011) ‘Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy’, Oncogene, 30(12), pp. 1379–1389. Available at: https://doi.org/10.1038/onc.2010.537.

Morris, E.C. and Stauss, H.J. (2016) ‘Optimizing T-cell receptor gene therapy for hematologic malignancies’, Blood, 127(26), pp. 3305–3311. Available at: https://doi.org/10.1182/blood-2015-11-629071.

Palucka, K. and Banchereau, J. (2012) ‘Cancer immunotherapy via dendritic cells’, Nature Reviews Cancer, 12(4), pp. 265–277. Available at: https://doi.org/10.1038/nrc3258.

Pierangeli, A., Antonelli, G. and Gentile, G. (2015) ‘Immunodeficiency-associated viral oncogenesis’, Clinical Microbiology and Infection, 21(11), pp. 975–983. Available at: https://doi.org/10.1016/j.cmi.2015.07.009.

Reichert, J.M. (2012) ‘Marketed therapeutic antibodies compendium’, mAbs, 4(3), pp. 413–415. Available at: https://doi.org/10.4161/mabs.19931.

Reichert, J.M. (2016) ‘Antibodies to watch in 2016’, mAbs, 8(2), pp. 197–204. Available at: https://doi.org/10.1080/19420862.2015.1125583.

Reichert, J.M. (2017) ‘Antibodies to watch in 2017’, mAbs, 9(2), pp. 167–181. Available at: https://doi.org/10.1080/19420862.2016.1269580.

Restifo, N.P., Dudley, M.E. and Rosenberg, S.A. (2012) ‘Adoptive immunotherapy for cancer: harnessing the T cell response’, Nature Reviews Immunology, 12(4), pp. 269–281. Available at: https://doi.org/10.1038/nri3191.

Robbins, P.F. et al. (2011) ‘Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1’, Journal of Clinical Oncology, 29(7), pp. 917–924. Available at: https://doi.org/10.1200/JCO.2010.32.2537.

Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth (2011) ‘Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion’, Science, 331(6024), pp. 1565–1570. Available at: http://www.jstor.org/stable/29783923?seq=1#page_scan_tab_contents.

Roos, W.P., Thomas, A.D. and Kaina, B. (2015) ‘DNA damage and the balance between survival and death in cancer biology’, Nature Reviews Cancer, 16(1), pp. 20–33. Available at: https://doi.org/10.1038/nrc.2015.2.

Russell, S.J., Peng, K.-W. and Bell, J.C. (2012) ‘Oncolytic virotherapy’, Nature Biotechnology, 30(7), pp. 658–670. Available at: https://doi.org/10.1038/nbt.2287.

Schinzari, V., Barnaba, V. and Piconese, S. (2015) ‘Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors’, Clinical Microbiology and Infection, 21(11), pp. 969–974. Available at: https://doi.org/10.1016/j.cmi.2015.06.026.

Schumacher, T.N. and Schreiber, R.D. (2015) ‘Neoantigens in cancer immunotherapy’, Science, 348(6230), pp. 69–74. Available at: https://doi.org/10.1126/science.aaa4971.

Shankaran, V. et al. (2001) ‘IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity’, Nature, 410(6832), pp. 1107–1111. Available at: https://doi.org/10.1038/35074122.

Spurgeon, M.E. and Lambert, P.F. (2013) ‘Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential’, Virology, 435(1), pp. 118–130. Available at: https://doi.org/10.1016/j.virol.2012.09.029.

Topalian, S.L. et al. (2012) ‘Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer’, New England Journal of Medicine, 366(26), pp. 2443–2454. Available at: https://doi.org/10.1056/NEJMoa1200690.

Varghese, S. and Rabkin, S.D. (2002) ‘Oncolytic herpes simplex virus vectors for cancer virotherapy’, Cancer Gene Therapy, 9(12), pp. 967–978. Available at: https://doi.org/10.1038/sj.cgt.7700537.

Weinberg, R.A. (2014) The biology of cancer. 2nd ed. New York: Garland Science.

Weiss, R.A. and Vogt, P.K. (2011) ‘100 years of Rous sarcoma virus’, The Journal of Experimental Medicine, 208(12), pp. 2351–2355. Available at: https://doi.org/10.1084/jem.20112160.

Wendzicki, J.A., Moore, P.S. and Chang, Y. (2015) ‘Large T and small T antigens of Merkel cell polyomavirus’, Current Opinion in Virology, 11, pp. 38–43. Available at: https://doi.org/10.1016/j.coviro.2015.01.009.